Palbociclib is a selective oral inhibitor of CDKs 4 and 6. CDKs 4 and 6 specifically are the key regulators of the cell cycle, involved in order to trigger the cellular progression. It is the first CDK 4/6 inhibitor approved by the U.S. FDA.
The palbociclib 125 mg tablet should be taken with food in together with the letrozole. In case of vomits or missed dose, an additional dose should not be administered that day.
Palbociclib capsules are swallowed whole (do not crush, chew, or open them prior to swallowing). No capsule is ingested in case it is cracked, broken, or otherwise not intact.